Reference
Cooper TP. Rivaroxaban (Xarelto): Increase in all-cause mortality, thromboembolic and bleeding events in patients after transcatheter aortic valve replacement in a prematurely stopped clinical trial. Internet Document : [3 pages], 3 Oct 2018. Available from: URL: https://www.hpra.ie/docs/default-source/default-document-library/important-safety-information
Rights and permissions
About this article
Cite this article
Phase III trial of rivaroxaban (Xarelto) prematurely stopped. Reactions Weekly 1724, 2 (2018). https://doi.org/10.1007/s40278-018-52981-6
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-018-52981-6